
AIM ImmunoTech Revenue | AIM
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AIM ImmunoTech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88 K | 170 K | 202 K | 141 K | 135 K | 163 K | 140 K | 367 K | 437 K | 92 K | 133 K | 197 K | 150 K | 213 K | 161 K | 27 K | 111 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 437 K | 27 K | 172 K |
Quarterly Revenue AIM ImmunoTech
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 K | 26 K | 22 K | 21 K | 26 K | 25 K | 16 K | 45 K | 35 K | 50 K | 40 K | 65 K | 46 K | 42 K | 49 K | - | 21 K | 30 K | 33 K | - | 33 K | 23 K | 28 K | - | 36 K | 40 K | 45 K | - | 61 K | 29 K | - | - | 38 K | 33 K | 56 K | - | 90 K | 213 K | 84 K | - | 22 K | 15 K | 39 K | - | 23 K | 47 K | 36 K | 40 K | 45 K | 36 K | 76 K | 36 K | 36 K | 36 K | 42 K | 53 K | 39 K | 49 K | 72 K | 38 K | 45 K | 36 K | 42 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 213 K | 15 K | 43.1 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Adaptimmune Therapeutics plc
ADAP
|
178 M | - | -15.15 % | $ 60.3 M | ||
|
TFF Pharmaceuticals
TFFP
|
734 K | - | -60.05 % | $ 125 K | ||
|
Codiak BioSciences
CDAK
|
22.9 M | - | -55.98 % | $ 2.15 M | ||
|
Sage Therapeutics
SAGE
|
41.2 M | - | - | $ 527 M | ||
|
Paratek Pharmaceuticals
PRTK
|
160 M | - | - | $ 121 M | ||
|
AVEO Pharmaceuticals
AVEO
|
17.6 M | - | - | $ 521 M | ||
|
Cyclerion Therapeutics
CYCN
|
2.07 M | $ 34.99 | 3.77 % | $ 147 M | ||
|
Seelos Therapeutics
SEEL
|
2.2 M | - | -47.76 % | $ 6.27 M | ||
|
Завод ДИОД
DIOD
|
517 M | - | - | - | ||
|
Deciphera Pharmaceuticals
DCPH
|
163 M | - | - | $ 2.18 B | ||
|
Fusion Pharmaceuticals
FUSN
|
2.07 M | - | - | $ 1.41 B | ||
|
Gritstone Oncology
GRTS
|
16.3 M | - | 0.42 % | $ 213 M | ||
|
Aridis Pharmaceuticals
ARDS
|
3.09 M | - | 17.91 % | $ 11.1 M | ||
|
Titan Pharmaceuticals
TTNP
|
184 K | - | -3.76 % | $ 3.47 M | ||
|
HOOKIPA Pharma
HOOK
|
43.9 M | - | -6.92 % | $ 79.4 M | ||
|
Otonomy
OTIC
|
125 K | - | -1.96 % | $ 4.68 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
268 M | $ 286.96 | 0.01 % | $ 5.55 B | ||
|
Фармсинтез
LIFE
|
372 M | - | - | - | ||
|
Actinium Pharmaceuticals
ATNM
|
90 K | $ 1.04 | -4.59 % | $ 32.4 M | ||
|
Oncternal Therapeutics
ONCT
|
785 K | - | -24.12 % | $ 1.56 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | ||
|
Concert Pharmaceuticals
CNCE
|
32.6 M | - | - | $ 401 M | ||
|
Histogen
HSTO
|
3.77 M | - | 31.6 % | $ 2.12 M | ||
|
Checkpoint Therapeutics
CKPT
|
41 K | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
36 M | - | -7.23 % | $ 13 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
573 M | - | - | $ 1.62 B | ||
|
Omeros Corporation
OMER
|
10.6 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
BioLineRx Ltd.
BLRX
|
1.18 M | $ 0.94 | -10.44 % | $ 2.32 B | ||
|
PhaseBio Pharmaceuticals
PHAS
|
10.8 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
7.44 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
509 M | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
3.63 B | - | - | $ 26.6 B | ||
|
Provention Bio
PRVB
|
12.9 M | - | - | $ 2.37 B | ||
|
Reata Pharmaceuticals
RETA
|
2.22 M | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
17 K | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
35 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
814 K | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
9.85 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
18.9 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
3.51 M | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
184 M | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
567 K | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
18.8 M | - | -23.43 % | $ 495 K | ||
|
BioXcel Therapeutics
BTAI
|
642 K | $ 0.07 | 9.81 % | $ 855 K |